Pharmaceutical giant plans $5.9B Houston facility and more news to know

Trending News

Eli Lilly is looking to Houston for a new facility. Getty Images

Editor's note: It's time to look back at the top Houston innovation news from the second half of May 2025. From exciting VC raises to major manufacturing facilities in the works, here are the most-read InnovationMap stories from May 16-30.

1. Pharmaceutical giant looks to bring $5.9 billion facility to Houston

Eli Lilly is looking to build an active pharmaceutical ingredient manufacturing facility at Generation Park. Rendering courtesy of McCord

Pharmaceutical company Eli Lilly and Company is looking to build a $5.9 billion active pharmaceutical ingredient (API) manufacturing facility in Houston, according to a recent filing with the state of Texas.

The proposal states that the project plans to employ 604 full-time direct employees at the site upon ramp-up completion. Construction is projected to begin in 2026, with a completion target of 2030 and commercial operations beginning in 2031. Continue reading.

2. Houston VC firm closes $21M fund for underrepresented founders

Zach Ellis, founder and general partner of South Loop Ventures, which recently closed its debut fund. Photo via LinkedIn

Houston-based South Loop Ventures recently closed its debut fund for more than $21 million, led by investments from Rice Management Company and Chevron Technology Ventures.

The funds will go toward teams with at least one underrepresented founder of color working in the energy, health, space, sports and fintech sectors. Additional investments came from The Great Commission Foundation of the Episcopal Diocese of Texas, Texas CapitalBank and others organizations. Continue reading.

3. Houston-founded startup raises $1.2M and moves headquarters to Detroit

ChurchSpace, founded in Houston by Day Edwards and Emmanuel Brown, is moving to Detroit. Photo courtesy ChurchSpace.

Houston-founded ChurchSpace, known as the Airbnb for churches, has formed an official partnership with the City of Detroit and will relocate its headquarters.

The announcements come as the company successfully closed a $1.2 million oversubscribed funding round. The round was led by California-based Black Ops Ventures, with participation from Michigan Rise and Dug Song of Minor Capital, who is also the founder of the Song Foundation, another Michigan-based organization. Continue reading.

4. Houston aerospace co. soars with first U.S. test flight of hypersonic engine

Venus Aerospace successfully completed the flight test of its hypersonic engine, the first of an American-developed engine of its kind. Photo courtesy Venus Aerospace

Houston-based Venus Aerospace successfully completed the first U.S. flight test of its proprietary engine at a demonstration at Spaceport America in New Mexico.

Venus’ next-generation rotating detonation rocket engine (RDRE) is supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA and aims to enable vehicles to travel four to six times the speed of sound from a conventional runway. The recent flight test was the first of an American-developed engine of its kind. Continue reading.

5. Houston regenerative medicine company expands lab for future trials

FibroBiologics has opened a new 10,000-square-foot Houston lab to scale up research efforts and pave the way for in-house manufacturing. Photo via Fibrobiologics.com

A Houston regenerative medicine company has unveiled new laboratory space with the goal of expanding its pioneering science.

FibroBiologics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells. With its new space, the publicly traded company, which has more than 240 patents issued or pending, will be even better equipped to power forward with its research. Continue reading.

These five Houston startups raised the most funding in 2024, according to InnovationMap reporting. Photo via Getty Images

Big winners: 5 Houston companies that raised the most funding in 2024

year in review

Editor's note: As 2024 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. When it came to the money raised in Houston, these five startups raised the most, according to reporting done by InnovationMap. Be sure to click on each story to read the full article.

Fervo Energy secures $600M in multiple rounds

The latest deal brings Fervo's total funding secured this year to around $600 million. Photo courtesy of Fervo

Fervo secured a lot of fresh funding this year to deliver on its 100x growth plans. Most recently, the company announced that it has raised $255 million in new funding and capital availability. A $135 million corporate equity round was led by Capricorn’s Technology Impact Fund II and a $120 million letter of credit and term loan facility was granted by Mercuria, an independent energy and commodity group that previously invested in the company. Read more about the round.

In February, Fervo secured $244 million in a financing round led by Devon Energy, and in September, the company received a $100 million bridge loan for the first phase of its ongoing project in Utah. This project, known as Project Cape, represents a 100x growth opportunity for Fervo, as Latimer explained to InnovationMap earlier this year. As of now, Project Cape is fully permitted up to 2 GW and will begin generating electricity in 2026, per the company.

Solugen scores $213.6M to support new facility

The new Solugen facility is expected to reduce annual carbon emissions by up to 18 million kilograms. Photo courtesy of Solugen

Houston-based Solugen secured financing from the U.S. Department of Energy's Loan Programs Office in June to support its mission of producing clean chemicals.

The LPO's $213.6 million loan guarantee will go toward the construction of the company's 500,000-square-foot Bioforge Marshall facility in Southwest Minnesota, which broke ground in April and will produce bio-based chemical products to be used in wastewater treatment, construction, agriculture, and the energy sector. According to Solugen, the facility is expected to reduce annual carbon emissions by up to 18 million kilograms.

"American manufacturing is at a turning point, and we are proud to have the opportunity to work with the DOE in bringing critical chemical production capabilities onshore to communities like Marshall," Gaurab Chakrabarti, CEO of Solugen, says in a news release. "By scaling cutting-edge technologies, we are meeting domestic demand for innovative solutions and setting global standards for sustainable biomanufacturing." Read more about the round.

Cart.com brings in $130M in financing, series C extension

Cart.com announced a $25 million series C extension round and $105 million in debt refinancing from investment manager BlackRock. Photo courtesy of Cart.com

While 2024 was less lucrative for Houston-based Cart.com when it comes to VC activity, the scaleup did pull in significant funding.

The company, which operates a multichannel commerce platform, secured $105 million in debt refinancing from investment manager BlackRock in July.

The debt refinancing follows a recent $25 million series C extension round, bringing Cart.com’s series C total to $85 million. The scaleup’s valuation now stands at $1.2 billion, making it one of the few $1 billion-plus “unicorns” in the Houston area. Read more about the round.

Procyrion closes $57.7M series E to fund journey to FDA approval, commercialization

Procyrion has announced the closing of its series E round of funding. Photo via Getty Images

Houston-born and bred medical device company, Procyrion, has completed its series E with a raise of $57.7 million, including the conversion of $10 million of interim financing.

Procyrion is the company behind Aortix, a pump designed to be placed in the descending thoracic aorta of heart failure patients, which has been shown to improve cardiac performance in seriously ill subjects. The money raised will allow the company to proceed with a the DRAIN-HF Study, a pivotal trial that will be used for eventual FDA approval and commercialization.

The Aortix is the brainchild of Houston cardiologist Reynolds Delgado. According to Procyrion’s CSO, Jace Heuring, Delgado, gained some of his experience with devices for the heart working with legendary Texas Heart Institute surgeon O.H. “Bud” Frazier. He filed his first patents related to the Aortix in 2005. Read more about the round.

Utility Global raises $53M series C investment

Utility Global’s technology enables reduction of greenhouse gas emissions along with generation of low-carbon fuels and chemicals. Photo courtesy of Utility Global

Houston-based Utility Global, a maker of decarbonization-focused gas production technology, has raised $53 million in an ongoing series C round.

Among the participants in the round are Canada’s Ontario Power Generation Pension Plan, the XCarb Innovation Fund operated by Luxembourg-based steel company ArcelorMittal, Houston-based investment firm Ara Partners, and Saudi Aramco’s investment arm.

Also, Utility Global and ArcelorMittal have agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant. Read more about the round.

The deal brings Fervo's total funding secured this year to around $600 million. Photo courtesy of Fervo

Fast-growing Houston-based geothermal energy co. secures $255M in additional funding

show me the money

A Houston company that's responding to rising energy demand by harnessing geothermal energy through its technology has again secured millions in funding. The deal brings Fervo's total funding secured this year to around $600 million.

Fervo Energy announced that it has raised $255 million in new funding and capital availability. The $135 million corporate equity round was led by Capricorn’s Technology Impact Fund II with participating investors including Breakthrough Energy Ventures, CalSTRS, Congruent Ventures, CPP Investments, DCVC, Devon Energy, Galvanize Climate Solutions, Liberty Mutual Investments, Mercuria, and Sabanci Climate Ventures.

The funding will go toward supporting Fervo's ongoing and future geothermal projects.

“The demand for 24/7 carbon-free energy is at an all-time high, and Fervo is one of the only companies building large projects that will come online before the end of the decade,” Fervo CEO and Co-Founder Tim Latimer says in a news release. “Investors recognize that Fervo’s ability to get to scale quickly is vital in an evolving market that is seeing unprecedented energy demand from AI and other sources.”

Additionally, Fervo secured a $120 million letter of credit and term loan facility from Mercuria, an independent energy and commodity group that previously invested in the company.

“In surveying power markets across the U.S. today, the need for next-generation geothermal is undeniable,” Brian Falik, group chief investment officer of Mercuria, adds. “We believe in Fervo not just because their EGS approach is cost-effective, commercially viable, and already being deployed at scale, but because they set ambitious targets and consistently deliver.”

Other wins for Fervo this year include moving into its new headquarters in downtown Houston, securing a power purchase agreement with California, growing its partnership with Google, and being named amongst the year's top inventions by Time magazine.

Several Houston institutions scored funding from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

German biotech co. to relocate to Houston thanks to $4.75M CPRIT grant

money moves

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

$2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
$2 million to recruit Xufeng Chen from New York University to MD Anderson.
$2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

$9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
$2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
$1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
$1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
$449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

The Investment is expected to help expand Bot Auto's tech development in autonomous trucking that will focus on safety and operation efficiency. Photo courtesy of Bot Auto

Houston-based autonomous trucking tech co. raises $20M

fresh funding

A Houston-based autonomous vehicle technology company has raised early funding.

Bot Auto has announced the completion of its pre-series A funding round which was oversubscribed and raised $20 million. The round was led by investments from Brightway Future Capital, Cherubic Ventures, EnvisionX Capital, First Star Ventures, Linear Capital, M31 Capital, Taihill Venture, Uphonest Capital, and Welight Capital.

“As true believers in autonomous trucking, we're thankful for our investors' shared vision,” Xiaodi Hou, founder and CEO of Bot Auto, says in a news release. “Our strong commitment, combined with recent AI advancements and a sharpened focus on operational efficiency, has created a clear path to commercialization.”

The funds raised will be focused on developing the technology and will opt to avoid unnecessary hiring ahead of operational maturity, scaling the operational footprint prior to product readiness, over expansion and partnership debt. The company aims for a more sustainable and efficient future, and is hoping its engineers and AV executives help Bot Auto become an autonomous trucking game changer.

The Investment is expected to help expand Bot Auto's tech development in autonomous trucking that will focus on safety and operation efficiency.

“Our prospects for success have never been more promising,” Hou adds. “ We march forward, committed to bringing this transformative technology to humanity for a brighter future.”

Bot Auto’s vision aligns with the pioneering spirit of Houston’s legacy in space exploration, striving to achieve remarkable feats in technology and transportation. The company is dedicated to leveraging this investment to make significant strides in the US autonomous trucking industry, ultimately contributing to a more sustainable and efficient future.

Rice researchers are cleaning up when it comes to grants and competitions. Photo via Rice.edu

Rice University innovators claim prizes across health care, energy research

big wins

Undergraduate students from Rice University were awarded the top prize in a health innovation challenge.

Design by Biomedical Undergraduate Teams (DEBUT) Challenge, which is organized by the National Institutes of Health (NIH) and the non-profit organization VentureWell, selected medical device team UroFlo as its winner, claiming the $20,000 prize. The technology, a continuous bladder irrigation system, was recognized for its potential to revolutionize post-operative care and improve patient outcomes.

The winning team from Rice consists of 2024 bioengineering graduates Anushka Agrawal, Sahana Prasanna, Robert Heeter, Archit Chabbi, Kevin Li, and Richard Chan. The UroFlo system provides care to patients after surgery and reduces the burden on health care professionals by implementing state-of-the-art sensors and machine learning algorithms with a touchscreen user interface. This helps with data collection, processing and visualization. UroFlo promises to enhance the management of urinary tract infections (UTIs) and help prevent blood clots.

“We have learned so much from this process and we are really proud of what we have accomplished,” says Chabbi in a news release. “It’s truly rewarding to know that our work can impact patients’ experience and help improve quality of care. Over the many hours we spent working in the Oshman Engineering Design Kitchen (OEDK) at Rice, we’ve not only developed an amazing set of skills, but have also forged really strong connections with one-another and the nearby medical community at the Texas Medical Center.”

The award will be presented on Oct. 25 in Baltimore during the annual Biomedical Engineering Society (BMES) conference.

UroFlo was also with first place in the Johns Hopkins Healthcare Design Competition in the Post-Surgical Infection Management category; first place in the American Society for Artificial Internal Organs Student Design Competition; “Best Medical Device Technology Award” in the 2024 Huff Engineering Design Showcase and competition held by the OEDK; “Outstanding Bioengineering Design Project,” Rice Department of Bioengineering; “Best Presentation” in the Texas Children’s Hospital Surgical Research Day; finalist and “Best Engineering Project” in Rice’s 2024 Shapiro Research Showcases; and semi-finalist in the H. Albert Napier Rice Launch Challenge. UroFlo will continue after Rice, as the project will be developed further.

“We are all very passionate about biomedical engineering, and dedicated and committed to making a difference” Chan said in a news release. “We actually decided to continue to develop UroFlo after our graduation from Rice a few months ago with the hope of improving our innovative solution for urological care.”

In other news, Rice University’s Naomi Halas won $7.5 million over five years from the United States Department of Defense (DOD) Air Force Office of Scientific Research (AFOSR) with her project proposal Multidisciplinary University Research Initiative (MURI) for her project titled “Combining Nonequilibrium Chemistries with Atomic Precision,” which competed in the category “plasmon-controlled single-atom catalysis.”

“Combining Nonequilibrium Chemistries with Atomic Precision” addressed the need for more energy-efficient and less protocol-intensive chemical processes that involve using light to drive chemical reactions and single-atom “reactors” to catalyze chemical reactions that are nearly 100 percent specific in terms of reaction products.

Plasmons work when they make metal nanoparticles act like antennas, and certain designed reactor sites on their surfaces can then carry out chemical reactions at a fraction of the “energy expenditure of conventional industrial catalysts” according to a news release.

Rice University and Baylor College of Medicine have also received $2.8 million in funding from the National Heart, Lung, and Blood Institute (NHLBI) for their research on reducing inflammation and lung damage in acute respiratory distress syndrome (ARDS) patients.

“Cell Based Immunomodulation to Suppress Lung Inflammation and Promote Repair,” will be co-led byRice’s Omid Veiseh, a professor of bioengineering and faculty director of the Rice Biotech Launch Pad, and professor of surgery at Baylor Ravi Kiran Ghanta. They will develop a new translational cell therapy platform “ to allow a better local administration of cytokines to the lungs in order to suppress inflammation and potentially prevent lung damage in ARDS patients” according to a news release.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston health orgs lost $58M in canceled, stalled NIH grants, new report shows

research cuts

Seven institutions in the Houston area have lost nearly $60 million in grants from the National Institutes of Health (NIH) that were aimed at funding health research.

The Science & Community Impacts Mapping Project identified 37 cancelled or frozen NIH grants worth $58.7 million that were awarded to seven Houston-area institutions. The University of Texas Medical Branch at Galveston suffered the biggest loss — five grants totaling nearly $44.8 million.

The Harvard University T.H. Chan School of Public Health reported in May that over the previous several months across the U.S., the federal government had terminated roughly 2,100 NIH research grants worth around $9.5 billion.

In August, the U.S. Supreme Court derailed researchers’ efforts to reinstate almost $2 billion in research grants issued by NIH, according to Nature.com.

“Make no mistake: This was a decision critical to the future of the nation, and the Supreme Court made the wrong choice. History will look upon these mass National Institutes of Health (NIH) research grant terminations with shame,” the American Association of Medical Colleges said in a statement. “The Court has turned a blind eye to this grievous attack on science and medicine, and we call upon Congress to take action to restore the rule of law at NIH.”

Texas health researchers rely heavily on NIH grants and contracts. During the federal government’s 2024 budget year, NIH awarded $1.9 billion in grants and contracts that directly supported 30,553 jobs and more than $6.1 billion in economic activity in Texas, according to the United for Medical Research coalition.

Here’s a rundown of the cancelled and frozen NIH grants in the Houston area.

University of Texas Medical Branch at Galveston: Five cancelled or frozen grants, totalling approximately $44.8 million in funding lost.
Baylor College of Medicine: 17 grants cancelled or frozen, totalling approximately $8 million in funding lost
University of Houston. Five cancelled or frozen grants, totalling approximately $3.7 million in funding lost
University of Texas Health Science Center Houston: Five grants cancelled or frozen, totaling approximately $1.1 million in funding lost.
University of Texas MD Anderson Cancer Center: Two grants cancelled or frozen, totalling $831,581 in funding
Rice University. Two grants cancelled or frozen, totaling $254,645 in funding lost
Prairie View A&M University: One grant cancelled or frozen, totalling $31,771 in funding lost

Magnolia milkshake shop blends up a sweet partnership with Comcast Business

Treat Takeover

Comcast Business (CB) powers businesses of every size with fast and reliable phone, mobile, internet, cybersecurity, and television services. Houston’s local CB team also stands behind entrepreneurs and small businesses, knowing they’re the heart of thriving communities: driving growth, sparking innovation, and creating jobs close to home.

Magnolia hometown favorite Chill Milkshake and Waffle Bar was the site of Comcast Business’ latest road trip to treat customers to a cool and refreshingly free treat, picking up the tab for several hours for nearly 200 customers.

Chill Milkshake and Waffle Bar, Magnolia Surprise! Your order is free.Photo courtesy of Comcast Business

“We aren’t just about products and services, we are about building partnerships in our community and playing a supporting role, it means the world to us,” says Heather Orrico, vice president of Comcast Business in Texas.

Chill Milkshakes and Waffle Bar, located at 6606 FM 1488 Rd., Suite 110 in Magnolia, opened in December 2020 and has been a Comcast Business customer for the last two years.

Who would’ve thought you’d need WiFi to serve milkshakes and waffles? Technology runs almost every part of the business.

“In a world where people rarely carry cash anymore, we have to be able to process payments electronically and promptly. Otherwise, the day stops. Nobody wants that,” says owner Jeanie Rosett. “We count on WiFi to efficiently complete transactions and guest payments, process online orders, and keep our music lively.”

It's no surprise that Chill’s array of flavors and dedication to making the perfect milkshake (along with waffles and sandwiches) have earned them the title of best milkshake in Texas by USA Today, followed by ranking sixth-best milkshake in the nation by Travel + Leisure.

Chill’s family environment creates a space where everybody can hang out, or the kids can come on their own and parents feel they are safe. “Good WiFi keeps them connected,” says store manager Laura Mabery. “We also have people who stop in with their laptop, have a hotdog and a shake while continuing to work. We live in a world that needs to be connected! You can do that at Chill-Magnolia.”

A sticker in the window lets everyone know.Photo courtesy of Comcast Business

While Mabery and Rosett appreciate the upgrade in customer service and reliability that was missing from their previous service provider, they were honored and pleasantly surprised to be selected for the recent Comcast Business “take over.”

“It's reassuring to know that our internet needs are taken care of, but that Comcast Business also supports us as a hometown commodity,” says Mabery. “And a free Chill milkshake...what's not to love about that?"

Houston robotics co. unveils new robot that can handle extreme temperatures

Hot New Robot

Houston- and Boston-based Square Robot Inc.'s newest tank inspection robot is commercially available and certified to operate at extreme temperatures.

The new robot, known as the SR-3HT, can operate from 14°F to 131°F, representing a broader temperature range than previous models in the company's portfolio. According to the company, its previous temperature range reached 32°F to 104°F.

The new robot has received the NEC/CEC Class I Division 2 (C1D2) certification from FM Approvals, allowing it to operate safely in hazardous locations and to perform on-stream inspections of aboveground storage tanks containing products stored at elevated temperatures.

“Our engineering team developed the SR-3HT in response to significant client demand in both the U.S. and international markets. We frequently encounter higher temperatures due to both elevated process temperatures and high ambient temperatures, especially in the hotter regions of the world, such as the Middle East," David Lamont, CEO of Square Robot, said in a news release. "The SR-3HT employs both active and passive cooling technology, greatly expanding our operating envelope. A great job done (again) by our engineers delivering world-leading technology in record time.”

The company's SR-3 submersible robot and Side Launcher received certifications earlier this year. They became commercially available in 2023, after completing initial milestone testing in partnership with ExxonMobil, according to Square Robot.

The company closed a $13 million series B round in December, which it said it would put toward international expansion in Europe and the Middle East.

Square Robot launched its Houston office in 2019. Its autonomous, submersible robots are used for storage tank inspections and eliminate the need for humans to enter dangerous and toxic environments.

---

This article originally appeared on EnergyCapitalHTX.com.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME